SCYNEXIS, Inc. (SCYX)
SCYNEXIS, Inc. is a biopharmaceutical company focused on developing and commercializing innovative antifungal therapies. It is known for its oral antifungal drug, Brexafemme (ibrexafungerp), which is approved for the treatment of certain fungal infections. The company emphasizes research and development to address unmet medical needs in fungal diseases and expand its portfolio of antifungal agents.
Company News
A leading company engaged DelveInsight to conduct a comprehensive study on the myopia market, including prevalence, treatment patterns, and market forecasts across the APAC region. DelveInsight's analysis provided strategic insights to help the client optimize its market entry and differentiation strategies.
Shares of Resources Connection, Inc. (NASDAQ: RGP) rose sharply in pre-market trading following better-than-expected results for its second quarter. Resources Connection posted quarterly adjusted earnings of 28 cents per share, beating market estimates of 18 cents per share. The company’s quarterly sales came in at $163.1 million versus expect...
Verve Therapeutics (VERV) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Use these tips to identify penny stocks opportunities The post Penny Stocks: Technical Approach to Finding Opportunities appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.